181 related articles for article (PubMed ID: 32097079)
1. Evaluation of inferential methods for the net benefit and win ratio statistics.
Verbeeck J; Ozenne B; Anderson WN
J Biopharm Stat; 2020 Sep; 30(5):765-782. PubMed ID: 32097079
[TBL] [Abstract][Full Text] [Related]
2. The win odds: statistical inference and regression.
Song J; Verbeeck J; Huang B; Hoaglin DC; Gamalo-Siebers M; Seifu Y; Wang D; Cooner F; Dong G
J Biopharm Stat; 2023 Mar; 33(2):140-150. PubMed ID: 35946932
[TBL] [Abstract][Full Text] [Related]
3. Adjusting win statistics for dependent censoring.
Dong G; Huang B; Wang D; Verbeeck J; Wang J; Hoaglin DC
Pharm Stat; 2021 May; 20(3):440-450. PubMed ID: 33247544
[TBL] [Abstract][Full Text] [Related]
4. Robust statistical inference for matched win statistics.
Matsouaka RA
Stat Methods Med Res; 2022 Aug; 31(8):1423-1438. PubMed ID: 35578578
[TBL] [Abstract][Full Text] [Related]
5. The use of the win odds in the design of non-inferiority clinical trials.
Peng L
J Biopharm Stat; 2020 Sep; 30(5):941-946. PubMed ID: 32475213
[TBL] [Abstract][Full Text] [Related]
6. Analysis of small sample size studies using nonparametric bootstrap test with pooled resampling method.
Dwivedi AK; Mallawaarachchi I; Alvarado LA
Stat Med; 2017 Jun; 36(14):2187-2205. PubMed ID: 28276584
[TBL] [Abstract][Full Text] [Related]
7. A win ratio approach to comparing continuous non-normal outcomes in clinical trials.
Wang D; Pocock S
Pharm Stat; 2016 May; 15(3):238-45. PubMed ID: 26970432
[TBL] [Abstract][Full Text] [Related]
8. The asymptotic distribution of the Net Benefit estimator in presence of right-censoring.
Ozenne B; Budtz-Jørgensen E; Péron J
Stat Methods Med Res; 2021 Nov; 30(11):2399-2412. PubMed ID: 34633267
[TBL] [Abstract][Full Text] [Related]
9. Efficient statistical inference for a parallel study with missing data by using an exact method.
Shan G; Hutson A; Wilding GE; Ma C; Tian GL
J Biopharm Stat; 2019; 29(3):478-490. PubMed ID: 31017028
[TBL] [Abstract][Full Text] [Related]
10. The stratified win statistics (win ratio, win odds, and net benefit).
Dong G; Hoaglin DC; Huang B; Cui Y; Wang D; Cheng Y; Gamalo-Siebers M
Pharm Stat; 2023; 22(4):748-756. PubMed ID: 36808217
[TBL] [Abstract][Full Text] [Related]
11. Win statistics (win ratio, win odds, and net benefit) can complement one another to show the strength of the treatment effect on time-to-event outcomes.
Dong G; Huang B; Verbeeck J; Cui Y; Song J; Gamalo-Siebers M; Wang D; Hoaglin DC; Seifu Y; Mütze T; Kolassa J
Pharm Stat; 2023 Jan; 22(1):20-33. PubMed ID: 35757986
[TBL] [Abstract][Full Text] [Related]
12. The win ratio: Impact of censoring and follow-up time and use with nonproportional hazards.
Dong G; Huang B; Chang YW; Seifu Y; Song J; Hoaglin DC
Pharm Stat; 2020 May; 19(3):168-177. PubMed ID: 31671481
[TBL] [Abstract][Full Text] [Related]
13. Win Statistics in Observational Cancer Research: Integrating Clinical and Quality-of-Life Outcomes.
Chiaruttini MV; Lorenzoni G; Spolverato G; Gregori D
J Clin Med; 2024 May; 13(11):. PubMed ID: 38892983
[No Abstract] [Full Text] [Related]
14. An evaluation of inferential procedures for adaptive clinical trial designs with pre-specified rules for modifying the sample size.
Levin GP; Emerson SC; Emerson SS
Biometrics; 2014 Sep; 70(3):556-67. PubMed ID: 24766094
[TBL] [Abstract][Full Text] [Related]
15. Exact critical values for group sequential designs with small sample sizes.
Rom DM; McTague JA
J Biopharm Stat; 2020 Jul; 30(4):752-764. PubMed ID: 32151177
[TBL] [Abstract][Full Text] [Related]
16. Nonparametric statistical methods for cost-effectiveness analyses.
Dinh P; Zhou XH
Biometrics; 2006 Jun; 62(2):576-88. PubMed ID: 16918923
[TBL] [Abstract][Full Text] [Related]
17. The inverse-probability-of-censoring weighting (IPCW) adjusted win ratio statistic: an unbiased estimator in the presence of independent censoring.
Dong G; Mao L; Huang B; Gamalo-Siebers M; Wang J; Yu G; Hoaglin DC
J Biopharm Stat; 2020 Sep; 30(5):882-899. PubMed ID: 32552451
[TBL] [Abstract][Full Text] [Related]
18. Evidence synthesis analysis with prioritized benefit outcomes in oncology clinical trials.
Cui Y; Dong G; Kuan PF; Huang B
J Biopharm Stat; 2023 May; 33(3):272-288. PubMed ID: 36343174
[TBL] [Abstract][Full Text] [Related]
19. A comparison of bootstrap approaches for estimating uncertainty of parameters in linear mixed-effects models.
Thai HT; Mentré F; Holford NH; Veyrat-Follet C; Comets E
Pharm Stat; 2013; 12(3):129-40. PubMed ID: 23457061
[TBL] [Abstract][Full Text] [Related]
20. [The research protocol VI: How to choose the appropriate statistical test. Inferential statistics].
Flores-Ruiz E; Miranda-Novales MG; Villasís-Keever MÁ
Rev Alerg Mex; 2017; 64(3):364-370. PubMed ID: 29046032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
